Patterns and determinants of prescribed drug use among pregnant women in Adigrat general hospital, northern Ethiopia: a cross-sectional study.
Adolescent
Adult
Cross-Sectional Studies
Drug Prescriptions
/ standards
Drug Utilization
/ standards
Ethiopia
Female
Guideline Adherence
/ statistics & numerical data
Hospitals, General
/ standards
Humans
Practice Guidelines as Topic
Practice Patterns, Physicians'
/ standards
Pregnancy
Pregnancy Complications
/ drug therapy
Prenatal Care
/ statistics & numerical data
Prescription Drugs
/ therapeutic use
Retrospective Studies
Young Adult
Adigrat hospital
Determinants
Drug use
FDA risk classification
Pregnancy
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
15 Oct 2020
15 Oct 2020
Historique:
received:
03
10
2019
accepted:
09
10
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
18
5
2021
Statut:
epublish
Résumé
A vigilant prescription of drugs during pregnancy can potentially safeguard the growing fetus from the deleterious effect of the drug while attempting to manage the mother's health problems. There is a paucity of information about the drug utilization pattern in the area of investigation. Hence, this study was implemented to investigate the pattern of drug utilization and its associated factors among pregnant women in Adigrat general hospital, Northern Ethiopia. An institution-based cross-sectional study was conducted among randomly selected 314 pregnant women who attended obstetrics-gynecology and antenatal care units of the hospital. Relevant data were retrieved from the pregnant women's medical records and registration logbook. The drugs prescribed were categorized based on the United States Food and Drug Administration (US-FDA) fetal harm classification system. Data analysis was done using SPSS version 20 statistical software. Multivariate logistic regression was employed to analyze the association of the explanatory variables with the medication use, and p < 0.05 was declared statistically significant. The overall prescribed drug use in this study was found to be 87.7%. A considerable percentage of the study participants (41.4%) were prescribed with supplemental drugs (iron folate being the most prescribed drug) followed by antibiotics (23.4%) and analgesics (9.2%). According to the US-FDA drug's risk classification, 42.5, 37, 13, and 7% of the drugs prescribed were from categories A, B, C, and D or X respectively. Prescribed drug use was more likely among pregnant women who completed primary [AOR = 5.34, 95% CI (1.53-18.6)] and secondary education [AOR = 4.1, 95% CI (1.16-14)], who had a history of chronic illness [AOR = 7.9, 95% CI (3.14-19.94)] and among multigravida women [AOR = 2.9, 95% CI (1.57 5.45)]. The finding of this study revealed that a substantial proportion of pregnant women received drugs with potential harm to the mother and fetus. Reasonably, notifying health practitioners to rely on up-to-date treatment guidelines strictly is highly demanded. Moreover, counseling and educating pregnant women on the safe and appropriate use of medications during pregnancy are crucial to mitigate the burden that the mother and the growing fetus could face.
Sections du résumé
BACKGROUND
BACKGROUND
A vigilant prescription of drugs during pregnancy can potentially safeguard the growing fetus from the deleterious effect of the drug while attempting to manage the mother's health problems. There is a paucity of information about the drug utilization pattern in the area of investigation. Hence, this study was implemented to investigate the pattern of drug utilization and its associated factors among pregnant women in Adigrat general hospital, Northern Ethiopia.
METHODS
METHODS
An institution-based cross-sectional study was conducted among randomly selected 314 pregnant women who attended obstetrics-gynecology and antenatal care units of the hospital. Relevant data were retrieved from the pregnant women's medical records and registration logbook. The drugs prescribed were categorized based on the United States Food and Drug Administration (US-FDA) fetal harm classification system. Data analysis was done using SPSS version 20 statistical software. Multivariate logistic regression was employed to analyze the association of the explanatory variables with the medication use, and p < 0.05 was declared statistically significant.
RESULTS
RESULTS
The overall prescribed drug use in this study was found to be 87.7%. A considerable percentage of the study participants (41.4%) were prescribed with supplemental drugs (iron folate being the most prescribed drug) followed by antibiotics (23.4%) and analgesics (9.2%). According to the US-FDA drug's risk classification, 42.5, 37, 13, and 7% of the drugs prescribed were from categories A, B, C, and D or X respectively. Prescribed drug use was more likely among pregnant women who completed primary [AOR = 5.34, 95% CI (1.53-18.6)] and secondary education [AOR = 4.1, 95% CI (1.16-14)], who had a history of chronic illness [AOR = 7.9, 95% CI (3.14-19.94)] and among multigravida women [AOR = 2.9, 95% CI (1.57 5.45)].
CONCLUSIONS
CONCLUSIONS
The finding of this study revealed that a substantial proportion of pregnant women received drugs with potential harm to the mother and fetus. Reasonably, notifying health practitioners to rely on up-to-date treatment guidelines strictly is highly demanded. Moreover, counseling and educating pregnant women on the safe and appropriate use of medications during pregnancy are crucial to mitigate the burden that the mother and the growing fetus could face.
Identifiants
pubmed: 33059613
doi: 10.1186/s12884-020-03327-7
pii: 10.1186/s12884-020-03327-7
pmc: PMC7558672
doi:
Substances chimiques
Prescription Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
624Références
BMC Pregnancy Childbirth. 2014 Sep 18;14:325
pubmed: 25233893
BMC Pregnancy Childbirth. 2016 Sep 20;16:272
pubmed: 27644958
Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):895-902
pubmed: 21774029
BJOG. 2006 May;113(5):559-68
pubmed: 16637899
Drug Saf. 1996 Feb;14(2):69-77
pubmed: 8852521
BMC Pregnancy Childbirth. 2019 Dec 3;19(1):459
pubmed: 31795963
Int J Med Sci. 2005;2(3):100-6
pubmed: 16007261
Matern Child Health J. 2018 Jan;22(1):92-100
pubmed: 28900803
BMC Pregnancy Childbirth. 2008 Jul 15;8:24
pubmed: 18627607
Int J Clin Pharm. 2013 Jun;35(3):408-16
pubmed: 23386140
Aust Fam Physician. 2000 Mar;29(3):237-41
pubmed: 10785989
N Engl J Med. 1998 Apr 16;338(16):1128-37
pubmed: 9545362
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):802-811
pubmed: 28449197
P T. 2016 Nov;41(11):713-715
pubmed: 27904304
Eur J Clin Pharmacol. 2006 Jul;62(7):547-53
pubmed: 16673101
BMC Pregnancy Childbirth. 2018 Nov 20;18(1):450
pubmed: 30458752
PLoS One. 2018 Jun 19;13(6):e0198618
pubmed: 29920515
BMC Res Notes. 2018 Dec 4;11(1):858
pubmed: 30514377
J Epidemiol Biostat. 2000;5(4):251-3
pubmed: 11055275
BMJ Open. 2014 Feb 17;4(2):e004365
pubmed: 24534260
BMC Pregnancy Childbirth. 2017 Jun 5;17(1):170
pubmed: 28583106
SAGE Open Med. 2020 Jun 20;8:2050312120935471
pubmed: 32612829
BMC Pregnancy Childbirth. 2018 Jun 1;18(1):200
pubmed: 29859057
BMC Pregnancy Childbirth. 2006 May 30;6:18
pubmed: 16734900
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):462-8
pubmed: 19334033
BMC Res Notes. 2019 Sep 18;12(1):592
pubmed: 31533806
Am J Obstet Gynecol. 2002 Aug;187(2):333-9
pubmed: 12193921
Drug Saf. 2000 Sep;23(3):245-53
pubmed: 11005706
Eur J Clin Pharmacol. 2000 Jul;56(4):323-8
pubmed: 10954347
J Paediatr Child Health. 2004 Mar;40(3):152-3
pubmed: 15009583
BMC Public Health. 2014 Jun 14;14:607
pubmed: 24930036
Int J Clin Pharm. 2011 Aug;33(4):634-41
pubmed: 21597985